EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advancements in nose-to-brain drug targeting for Alzheimer’s disease: a review of nanocarriers and clinical insights

Kumari Komal, Rashmi Ghosh, Debayan Sil, Rohit Sharma, Sourabh Kumar, Prachi Pandey, Manish Kumar

Inflammopharmacology · 2025

DOI: 10.1007/s10787-024-01636-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Kumari Komal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Delivery Systems, Nanoparticles, Brain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 133 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a type of neurodegenerative disease that describes cognitive decline and memory loss resulting in disability in movement, memory, speech etc. Which first affects the hippocampal and entorhinal cortex regions of brain. Pathogenesis of AD depends on Amyloid-β, hyper-phosphorylation of tau protein, mitochondrial dysfunction, cholinergic hypothesis and oxidative stress. In comparison with males, females are more prone to AD due to reduced estrogen level. Some of the FDA-approved drugs and their conventional formulations available in the market are discussed in this review. Nose-to-brain delivery system provides the target specific drug delivery via olfactory and trigeminal nerve (active and passive drug targeting strategies) and bypassing the Blood Brain Barrier. Mucoadhesive agents and permeation enhancers are mostly utilized to enhance the retention time and bioavailability of the drugs. Liposomes, niosomes, cubosomes, solid lipid nanoparticles, nanoemulsions, micelles, and many more nanocarriers for nose-to-brain delivery of drugs are also described thoroughly in this review. It also covers the clinical trials and patents for nose-to-brain delivery. In this article, we investigate the nose-to-brain pathways for AD treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDrug Delivery SystemsNanoparticlesBrainDrug CarriersHumansAnimalsAdministration, IntranasalBlood-Brain BarrierNasal Mucosa

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid plaquesNanocarriersNasal cavityNeurofibrillary tanglesNose-to-brain delivery

Substanzen

Drug Carriers

Autor:innen und Institutionen

  • Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India.
  • Department of Pharmaceutical Quality Assurance, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India.
  • Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India. manish_singh17@rediffmail.com.

Zitieren

APA

Komal, K., Ghosh, R., Sil, D., Sharma, R., Kumar, S., Pandey, P., & Kumar, M. (2025). Advancements in nose-to-brain drug targeting for Alzheimer’s disease: a review of nanocarriers and clinical insights. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01636-3

Vancouver

Komal K, Ghosh R, Sil D, Sharma R, Kumar S, Pandey P, et al. Advancements in nose-to-brain drug targeting for Alzheimer’s disease: a review of nanocarriers and clinical insights. Inflammopharmacology. 2025. doi:10.1007/s10787-024-01636-3

BibTeX
@article{Komal2025,
  author = {Komal, Kumari and Ghosh, Rashmi and Sil, Debayan and Sharma, Rohit and Kumar, Sourabh and Pandey, Prachi and Kumar, Manish},
  title = {Advancements in nose-to-brain drug targeting for Alzheimer’s disease: a review of nanocarriers and clinical insights},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-024-01636-3}
}
Kostenlos starten →